标题:Driving better and safer HER2-specific CARs for cancer therapy
作者:Liu, Xianqiang; Zhang, Nan; Shi, Huan
作者机构:[Liu, Xianqiang] Shandong Univ, Jinan Cent Hosp, Dept Breast & Thyroid Surg, Jinan 250013, Shandong, Peoples R China.; [Zhang, Nan] Shandong Univ, J 更多
通讯作者:Shi, H
通讯作者地址:[Shi, H]Shandong Univ, Shandong Acad Med Sci, Shandong Canc Hosp, Dept Oncol, Jinan, Shandong, Peoples R China.
来源:ONCOTARGET
出版年:2017
卷:8
期:37
页码:62730-62741
DOI:10.18632/oncotarget.17528
关键词:chimeric antigen receptor; HER2; cancer; immunotherapy; toxicity
摘要:Given the clinical efficacy of chimeric antigen receptor (CAR)-based therapy in hematological malignancies, CAR T-cell therapy for a number of solid tumors has been actively investigated. Human epidermal growth factor receptor 2 (HER2) is a well-established therapeutic target in breast, as well as other types of cancer. However, HER2 CAR T cells pose a risk of lethal toxicity including cytokine release syndrome from "on-target, off-tumor" recognition of HER2. In this review, we summarize the development of conventional HER2 CAR technology, the alternative selection of CAR hosts, the novel HER2 CAR designs, clinical studies and toxicity. Furthermore, we also discuss the main strategies for improving the safety of HER2 CAR-based cancer therapies.
收录类别:SCOPUS;SCIE
WOS核心被引频次:3
Scopus被引频次:1
资源类型:期刊论文
原文链接:https://www.scopus.com/inward/record.uri?eid=2-s2.0-85028747705&doi=10.18632%2foncotarget.17528&partnerID=40&md5=37b2c9294ca2071419bd988317f5261b
TOP